Abstract

Simple SummarySelective internal radiation therapy (SIRT) is a treatment for patients with liver cancer that involves the injection of radioactive microspheres into the liver artery. For a successful treatment, it is important that tumours are adequately covered with these microspheres; however, there is currently no method to assess this intraoperatively. As holmium microspheres are paramagnetic, MRI can be used to visualize the holmium deposition directly after administration, and possibly to adapt the treatment if necessary. In order to exploit this advantage and provide a personally optimized approach to SIRT, the administration could ideally be performed within a clinical MRI scanner. It is, however, unclear whether all materials (catheters, administration device) used during the procedure are safe for use in the MRI suite. Additionally, we explore the capability of MRI to visualize the microspheres in near real-time during injection, which would be a requirement for successful MRI-guided treatment. We further illustrate our findings with an initial patient case.Selective internal radiation therapy (SIRT) is a treatment modality for liver tumours during which radioactive microspheres are injected into the hepatic arterial tree. Holmium-166 (166Ho) microspheres used for SIRT can be visualized and quantified with MRI, potentially allowing for MRI guidance during SIRT. The purpose of this study was to investigate the MRI compatibility of two angiography catheters and a microcatheter typically used for SIRT, and to explore the detectability of 166Ho microspheres in a flow phantom using near real-time MRI. MR safety tests were performed at a 3 T MRI system according to American Society for Testing of Materials standard test methods. To assess the near real-time detectability of 166Ho microspheres, a flow phantom was placed in the MRI bore and perfused using a peristaltic pump, simulating the flow in the hepatic artery. Dynamic MR imaging was performed using a 2D FLASH sequence during injection of different concentrations of 166Ho microspheres. In the safety assessment, no significant heating (ΔTmax 0.7 °C) was found in any catheter, and no magnetic interaction was found in two out of three of the used catheters. Near real-time MRI visualization of 166Ho microsphere administration was feasible and depended on holmium concentration and vascular flow speed. Finally, we demonstrate preliminary imaging examples on the in vivo catheter visibility and near real-time imaging during 166Ho microsphere administration in an initial patient case treated with SIRT in a clinical 3 T MRI. These results support additional research to establish the feasibility and safety of this procedure in vivo and enable the further development of a personalized MRI-guided approach to SIRT.

Highlights

  • In interventional oncology, selective internal radiation therapy (SIRT) has become an established treatment modality for primary and secondary liver malignancies [1,2]

  • Even though Selective internal radiation therapy (SIRT) has been used in clinical practice for over 20 years, the exact mechanisms behind the distribution of microspheres remain a ‘black box’, and this complicates the prediction of dose distribution and response

  • In preparation for a clinical trial designed to investigate the feasibility of an MRIguided approach to SIRT in salvage patients [17], we addressed several hurdles that needed to be overcome to allow SIRT to be delivered in a clinical MRI environment

Read more

Summary

Introduction

Selective internal radiation therapy (SIRT) has become an established treatment modality for primary and secondary liver malignancies [1,2]. Radioactive microspheres containing the beta-emitters yttrium-90 (90 Y) or holmium-166 (166 Ho) are injected into the hepatic arterial tree and transported through the perfused liver volume until they get stuck in the arterioles because of their size. Both isotopes are high-energy β-emitters (90 Y: Eβ-max = 2.28 MeV (100%), 166 Ho: Eβ-max = 1.85 MeV (48.8%), 1.77 MeV (49.9%)) and their half-lives are 64.2 (90 Y) and 26.8 h (166 Ho) [3,4]. Imaging to visualize the actual dose distribution is typically performed through 90 Y-PET/CT [8] or 166 Ho-SPECT/CT [9,10] in the hours to days after treatment

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call